Jonathan Nash, MD, Investment Principal at LifeArc Ventures, congratulates portfolio company, Cytospire, on their £61 million Series A fundraise
Date
May 5, 2026
Location
London
“LifeArc Ventures is excited to continue supporting Cytospire as it advances its pipeline of first-in-class pan-gamma delta T cell engagers towards the clinic. This oversubscribed Series A, backed by a high-quality syndicate of specialist investors, speaks to the strength of the company’s science, the progress made by the team, and the potential of Cytospire’s approach to deliver meaningful new treatment options for patients.”
